Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

@article{Nashan1997RandomisedTO,
  title={Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.},
  author={Bjorn A P Nashan and Richard Moore and Peter L. Amlot and Albrecht G. Schmidt and K. R. W. Abeywickrama and Jean Paul Soulillou},
  journal={Lancet},
  year={1997},
  volume={350 9086},
  pages={1193-8}
}
BACKGROUND Currently available immunosuppressive regimens for cadaver-kidney recipients are far from ideal because acute-rejection episodes occur in about 30% to 50% of these patients. In the phase III study described here we assessed the ability of basiliximab, a chimeric interleukin (IL)-2 receptor monoclonal antibody, to prevent acute-rejection episodes in renal allograft recipients. METHODS 380 adult recipients of a primary cadaveric kidney transplant were randomly allocated, in this… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
123 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 123 extracted citations

Similar Papers

Loading similar papers…